Ion channels are essential for the electrical activity of excitable cells and play critical roles in non-excitable tissues as well. They are key targets for treating a variety of medical conditions, including heart rhythm disorders, high blood pressure, the effects of local anesthetics, pain relief, stroke mitigation, epilepsy, mood disorders like depression and bipolar disorder, chronic obstructive pulmonary disease (COPD), autoimmune conditions, and diabetes. Their importance extends to drug development, where they serve not only as targets for new medications but also as essential biomarkers for evaluating drug safety. 

In the drug discovery process, pinpointing a compound’s target specificity through selectivity profiling and conducting safety assessments are vital steps. Many drugs withdrawn from the market due to cardiac-related adverse effects have been shown to block the human ether-a-go-go (hERG) ion channel. 

ICE Bioscience boasts an extensive array of validated assays for profiling the selectivity of ion channels. Our comprehensive ion channel suite encompasses more than 100 stable cell lines, meticulously categorized into different portfolios in alignment with the latest scientific insights. We are equipped to deliver a spectrum of ion channel screening services, ranging from manual patch clamp to automated patch clamp and FLIPR assays, tailored to therapeutic areas for profiling, risk assessment, and mechanism of action (MoA) research.

ICE Bioscience Ion Channel Profiling:

▶ Cardiac Channel Panel 

▶ Cardiovascular Channel Panel 

▶ Pain-Inflammation Channel Panel 

▶ Seizure-Convulsion Channel Panel 

▶ Cancer Channel Panel 

▶ Metabolic GI Channel Panel 

▶ Neurodegeneration/Stroke Channel Panel 

▶ Pulmonary-Respiratory Channel Panel 

▶ Psychiatric Disorder Channel Panel 

▶ Genitourinary Channel Panel

▶ Depression Panel

DOWNLOAD THE TARGET LIST